Locations:

Blood Cancers

December 7, 2015/Cancer/Blood Cancers

Analysis of Molecular Mutations in AML and MDS Have Prognostic Impact on Outcomes After Allogeneic HCT

Complex karyotypes, TET2 mutations lower survival rates

December 7, 2015/Cancer/Blood Cancers

Radioactive Iodine Treatment of Thyroid Cancers Increases Risk of MDS

Cleveland Clinic researchers warn against overtreatment

December 7, 2015/Cancer/Blood Cancers

Standard-of-Care Treatment Often Ignored for Cancer-Associated Thrombosis

Insurance data analysis uncovers real-world behaviors

December 7, 2015/Cancer/Blood Cancers

Trial Finds Advantage in Overall Response Rate for subtypes of MDS Patients Receiving Azacitidine Combination Therapy

Response in patient subgroups shows promise, however

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

December 7, 2015/Cancer/Blood Cancers

Cancer Patients with High Risk for Blood Clots May Benefit from Preventive Anticoagulant Treatment

Screening high-risk patients early may be the way to go

December 6, 2015/Cancer/Blood Cancers

Expanding Clones Seen in Minority of Patients With Aplastic Anemia Treated With Eltrombopag

Researchers suspect that mutations may be leukemogenic

October 7, 2015/Cancer/Blood Cancers

Noncytotoxic Differentiation Treatment

Correcting an irrational imbalance in oncotherapeutic care

February 20, 2015/Cancer/Blood Cancers

Optimizing Multiple Myeloma Therapy with a Care Path

Response-adapted therapy plan shows promise

February 14, 2015/Cancer/Blood Cancers

Patient Socioeconomic Status Impacts Long-Term Outcomes After Allogeneic Hematopoietic Cell Transplant

Study shows lower-income transplant recipients have reduced overall survival

February 11, 2015/Cancer/Blood Cancers

Bortezomib-based Induction Therapy Before Transplant Benefits Amyloidosis Patients

Cleveland Clinic study finds regimen helps improve outcomes

BackPage 7 of 8Next